PFE · News · 20260921N
Guidance and Outlook
PFIZER INC · 2026-09-21 · Importance 75 · Surprise 60 · No source text
Third-party reporting states Pfizer is $1.5 billion ahead of its original 2026 base-business guidance. Management is targeting $9.7 billion of cost savings by 2029, which the report says should support dividend coverage through the patent cliff. The savings program is also expected to preserve funding for research and development investment.
Key facts
- Pfizer is $1.5B ahead of the original 2026 base business guidance. source
- PFE's non-COVID portfolio is growing 5% operationally. source
- Pfizer remains a compelling income play, offering a 6.22% yield and trading at 9.3x 2026 consensus EPS amid a rising-rate environment. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +10.0% | Pfizer is $1.5B ahead of the original 2026 base business guidance. |
| revenue | positive | realized | — | PFE's non-COVID portfolio is growing 5% operationally. |